The AquaBeam robotic system is a novel, minimally invasive technology indicated for treating Benign Prostatic Hyperplasia (BPH), one of the most common pathologies affecting men.

Benign prostatic hyperplasia (BPH ) is the benign enlargement of the prostate gland that obstructs the flow of urine from the bladder. This leads to a decline in the quality of urinary function in men, resulting in a weak stream, difficulty initiating urination, increased urinary frequency, nighttime urination, and a feeling of incomplete bladder emptying, ultimately diminishing their quality of life.

The AquaBeam robotic system allows the ablation of prostate tissue (BPH) by means of a jet or stream of physiological saline (water + sodium chloride) at a very high speed and high pressure (10.000 PSI), without using any type of thermal energy, unlike transurethral resection (TUR) and lasers.

The surgical procedure is controlled and performed using an ultrasound-guided robotic system. The surgeon, through continuous ultrasound and cystoscopic monitoring, plans the treatment in a personalized way and precisely assesses the volume of tissue that the robot must remove. This technology simultaneously combines cystoscope images with ultrasound images, all in real time.

These two imaging modalities provide the surgeon with a complete, multidimensional view of the entire prostate, allowing them to create a surgical map of the areas of the prostate that must be removed and those that must be avoided. Because each prostate is unique in size and shape, the map can be customized and adapted to each patient's unique anatomy.

Once all the parameters are integrated, the robot performs the procedure quickly, predictably, and accurately. After completion, a catheter is placed in the bladder, which is usually removed the following day, and the patient is typically discharged within 24-48 hours.